Alembic Pharmaceuticals Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Alembic Pharmaceuticals Ltd filed with BSE on 10 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Alembic Pharmaceuticals reported consolidated revenue growth of 26% year-on-year in Q1 FY27, driven by 37% growth in International Generics, 33% growth in the API business and 7% growth in the India branded business. Management raised its full-year FY27 revenue growth outlook to the mid-teen range from an earlier low double-digit expectation, citing stronger than expected US Generics performance including the launch of Bosutinib. EBITDA grew 21% year-on-year to Rs 348 crore with a 16% margin, while profit after tax grew 12% to Rs 173 crore reflecting a higher effective tax rate following migration to the new tax regime.
Numbers mentioned
Consolidated revenue growth: 26% (Q1 FY27)
p. 3
“During the quarter, consolidated revenue grew by 26% year-on-year supported by growth across all our major businesses.”
Pranav Amin, page 3 of the filed PDF · View the filing
India branded business growth: 7% (Q1 FY27)
p. 3
“India branded business grew 7%.”
Pranav Amin, page 3 of the filed PDF · View the filing
International Generics growth: 37% (Q1 FY27)
p. 3
“International Generics grew 37% and the API business grew 33%.”
Pranav Amin, page 3 of the filed PDF · View the filing
US revenue growth: 49% (Q1 FY27)
p. 4
“U.S. revenues grew 49% year-on-year, supported by volume growth, new launches, especially Bosutinib and improving utilization of our manufacturing assets.”
Pranav Amin, page 4 of the filed PDF · View the filing
Animal Health growth: 24% (Q1 FY27)
p. 3
“Animal Health delivered a particularly strong quarter with 24% growth, while key therapies such as Gynecology, Gastrology and Ophthalmology continued to perform well.”
Pranav Amin, page 3 of the filed PDF · View the filing
Revenue: INR2,150 crores (Q1 FY27)
p. 5
“Revenue grew at 26% year-on-year to INR2,150 crores, reflecting broad-based growth across businesses and continued momentum across the portfolio.”
G. Krishnan, page 5 of the filed PDF · View the filing
EBITDA: INR348 crores (Q1 FY27)
p. 5
“Reported EBITDA grew at 21% year-on-year to INR348 crores with EBITDA margin at 16%.”
G. Krishnan, page 5 of the filed PDF · View the filing
R&D expenditure: INR186 crores (Q1 FY27)
p. 5
“our R&D expenditure during the quarter was at INR186 crores, representing about 9% of revenue, driven by peptide development activities, exhibit batches and higher regulatory filings and portfolio development initiatives.”
G. Krishnan, page 5 of the filed PDF · View the filing
Profit before tax: INR223 crores (Q1 FY27)
p. 5
“Profit before tax grew at 17% year-on-year to INR223 crores, reflecting the strength of the underlying operating performance and better operating leverage across the business.”
G. Krishnan, page 5 of the filed PDF · View the filing
Effective tax rate: about 22% (Q1 FY27)
p. 5
“At PAT level, the quarter reflected a higher effective tax rate of about 22% compared with around 19% in the corresponding quarter previous year.”
G. Krishnan, page 5 of the filed PDF · View the filing
Profit after tax: INR173 crores (Q1 FY27)
p. 5
“profit after tax grew at 12% year-on-year to INR173 crores, underlining the resilience of the business performance.”
G. Krishnan, page 5 of the filed PDF · View the filing
Products launched: 7 products (Q1 FY27)
p. 4
“During the quarter, we launched 7 products, filed 4 ANDA's and received 10 approvals, further strengthening the launch platform for future growth.”
Pranav Amin, page 4 of the filed PDF · View the filing
Gross debt: INR1,600 crores (as of June 2026)
p. 16
“So gross debt was about -- we are at around INR1,600 crores of gross debt and 2 things have happened.”
G. Krishnan, page 16 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
US Generics revenue growth — mid to high teens · FY27
stated conditionally by Pranav Amin
p. 4
“we now expect the US business to grow mid to high teens in the year, subject to normal market conditions and continued execution.”
Pranav Amin, page 4 of the filed PDF · View the filing
Overall company revenue growth — mid-teen range · FY27
stated firmly by Pranav Amin
p. 4
“we believe the overall growth outlook for the company can improve from the low double-digit range that we had discussed earlier to closer to the mid-teen range for FY27.”
Pranav Amin, page 4 of the filed PDF · View the filing
EBITDA margin dilution from US branded business — 150 basis points · full year
stated firmly by G. Krishnan
p. 7
“for the full year, if I have to remind in the previous call, we guided about 150 basis points of dilution in the margin for the full year, and we hold on to that view at this point of time.”
G. Krishnan, page 7 of the filed PDF · View the filing
US branded business profitability contribution — positive contribution · next financial year
stated as an aspiration by Pranav Amin
p. 6
“I expect that this will start contributing positively next financial year onwards.”
Pranav Amin, page 6 of the filed PDF · View the filing
API business growth — around 10% · FY27
stated conditionally by Pranav Amin
p. 12
“Moving forward, I think at the end of the year, we will be above that 10% level, around the 10% level that we had mentioned.”
Pranav Amin, page 12 of the filed PDF · View the filing
India business growth relative to market — aligned to market growth · FY27
stated as an aspiration by G. Krishnan
p. 12
“So, it should be in the range of high single digit, but we will bridge the gap.”
G. Krishnan, page 12 of the filed PDF · View the filing
US product launches — 15-odd products · rest of FY27
stated firmly by Pranav Amin
p. 6
“Yes. I think for the rest of the year, we should be launching another 15-odd products.”
Pranav Amin, page 6 of the filed PDF · View the filing
ROW/ex-U.S. business growth — about 15% · FY27
stated conditionally by Pranav Amin
p. 10
“But at the end of the year, we stick to the guidance. I think about 15-odd percent or so of what I've guided for that the business will grow, and I think we're quite confident about that.”
Pranav Amin, page 10 of the filed PDF · View the filing
Gross debt levels — reasonably close to 1x of EBITDA · during the year
stated as an aspiration by G. Krishnan
p. 16
“So, we should -- at the minimum, we should go back to the March levels. And our intention is to scale it down further so that we are able to maintain it at a reasonably close to 1x of EBITDA.”
G. Krishnan, page 16 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said ex-Bosutinib business also grew strongly, driven by new product launches.
Answered by Pranav Amin
Asked by Damayanti Kerai: What drove the strong Q1 US business number beyond Bosutinib exclusivity?
p. 6
“I think ex of Bosutinib, also our business has grown over 20% in the US, closer to 25% that we've grown. That is predominantly due to the new launches.”
Pranav Amin, page 6 of the filed PDF · View the filing
Management expects the drag to reduce gradually with a positive contribution expected next financial year.
Answered by Pranav Amin
Asked by Damayanti Kerai: When will the US branded business start contributing positively to EBITDA?
p. 6
“As we move forward quarter-on-quarter, we will gradually see a reduction in the drag that this business is causing us. And my goal is that next year onwards, we should start seeing a positive contribution.”
Pranav Amin, page 6 of the filed PDF · View the filing
Management confirmed the Q1 impact on margins was higher than the 150bps full-year guidance but expects moderation ahead.
Answered by G. Krishnan
Asked by Chirag: Is the 150bps margin dilution guidance from the US branded business holding, and was Q1 impact higher?
p. 7
“And obviously, in the ramp-up phase, you will have the first few quarters of higher impact. And then as the sales picks up, it should moderate, the margin impact should moderate.”
G. Krishnan, page 7 of the filed PDF · View the filing
Management said it hopes the trend continues for the next quarter or two but flagged pricing erosion risk.
Answered by Pranav Amin
Asked by Chirag: Is the higher ex-Bosutinib US base run-rate the new normal?
p. 8
“I'm confident that the momentum that we have going forward, we should be able to continue some of it. Let's see how much price erosion we see for the next few quarters.”
Pranav Amin, page 8 of the filed PDF · View the filing
Management cited rising solvent prices, product mix, and a debottlenecking shutdown causing under-absorption of costs.
Answered by G. Krishnan
Asked by Chirag: What explained the flattish gross margins despite Bosutinib contribution?
p. 9
“One is, of course, with a bit of the Middle East issues going on, we had seen solvent prices going up. That has had a bit of impact.”
G. Krishnan, page 9 of the filed PDF · View the filing
Management said it will take a couple of quarters to see positive trends as new leadership works through territories.
Answered by Pranav Amin
Asked by Rahul Jeewani: When will India human health growth pick up following management changes?
p. 10
“I think it will take a couple of quarters because it's a work in progress.”
Pranav Amin, page 10 of the filed PDF · View the filing
Management clarified core margins are improving to high teens, partly offset by 150bps dilution from the US branded business.
Answered by Pranav Amin
Asked by Rahul Jeewani: What is the FY27 margin guidance given conflicting statements on high-teens and offsetting dilution?
p. 11
“my comment was about the core margin improving to high-teens and which will partially get offset by the margin dilution from US branded business, which we said will be about 150 basis points, right?”
Pranav Amin, page 11 of the filed PDF · View the filing
Management expects the API business to grow around or above the 10% level guided at the start of the year.
Answered by Pranav Amin
Asked by Rashmi Shetty: What is the outlook for the API segment for the year?
p. 12
“Seeing the trend, I think Q1 has been quite healthy. Moving forward, I think at the end of the year, we will be above that 10% level, around the 10% level that we had mentioned.”
Pranav Amin, page 12 of the filed PDF · View the filing
Management said receivables-driven debt increase should unwind and debt should reduce toward March levels or lower.
Answered by G. Krishnan
Asked by Rashmi Shetty: What is the outlook for gross debt and interest costs for the rest of the year?
p. 16
“So, as we progress during the quarter 2 and quarter 3, we should see this debt levels moderating.”
G. Krishnan, page 16 of the filed PDF · View the filing
Management said specialty is about 60% of India revenue and growth will come from better prescription quality and field productivity.
Answered by G. Krishnan
Asked by Foram Parekh: What is the current size of the chronic/specialty segment in India and the growth plan?
p. 14
“the specialty business is roughly about close to about 60% of our total revenue.”
G. Krishnan, page 14 of the filed PDF · View the filing
Risks flagged
Pricing pressure in the external environment
p. 3
“The external environment continues to remain competitive with pricing pressure, regulatory expectations and geopolitical uncertainties.”
Pranav Amin, page 3 of the filed PDF · View the filing
Uncertain sustainability of Bosutinib sales due to small volumes and potential competition
p. 8
“I don't know that when they will -- because it's such a low-volume product, I don't -- I can't really foresee what's going to happen after a few months.”
Pranav Amin, page 8 of the filed PDF · View the filing
Bosutinib exclusivity ending and competitive entry
p. 8
“I know this exclusivity is there till November. So you'll see Q2 and part of Q3, you will hopefully have some sales from Bosutinib.”
Pranav Amin, page 8 of the filed PDF · View the filing
Gross margin impact from rising solvent prices linked to Middle East issues
p. 9
“with a bit of the Middle East issues going on, we had seen solvent prices going up. That has had a bit of impact.”
G. Krishnan, page 9 of the filed PDF · View the filing
Under-absorption of costs from facility shutdown for debottlenecking
p. 9
“that shutdown was taken in the first quarter, which has resulted in a bit of under-absorption in the cost.”
G. Krishnan, page 9 of the filed PDF · View the filing
India human health business underperforming market growth due to management transition
p. 12
“It's few of the acute and some of the other divisions which are dragging the business down.”
Pranav Amin, page 12 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.